InSysBio Announces Collaboration on Quantitative System Pharmacology Modeling of Chronic Obstructive Pulmonary Disease

June 13, 2018

June 13, 2018

InSysBio LLC (, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a collaboration with GSK, one of the world’s leading research-based pharmaceutical and healthcare companies, for development of QSP platform of Chronic Obstructive Pulmonary Disease (COPD).

The aim of collaboration is to develop a comprehensive QSP platform of COPD and its treatment including detailed description of immune cell dynamics, effect of cigarette smoke, extracellular matrix remodeling and other aspects of disease progression.

About InSysBio

InSysBio (formerly Institute for System Biology Moscow) was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of quantitative systems pharmacology (QSP) modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published a lot of scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit